Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Seven versus 14 days of antimicrobial therapy for severe multidrug-resistant Gram-negative bacterial infections in intensive care unit patients (OPTIMISE): a randomised, open-label, non-inferiority clinical trial.
Arns B, Kalil AC, Sorio GGL, Boschi E, Antonio ACP, Antonio JP, Birriel DC, Lanziotti DH, da Cunha Abbott F, Rocha GC, de Fátima Fernandes V, de Souza Dantas VC, da Silva Medeiros GF, de França Diniz Rocha V, Pereira FC, Gobatto ALN, Lima VP, Lacerda FH, de Maio Carrilho CMD, de Oliveira Cardozo KDN, Irineu VM, Kurtz P, Horvath JDC, Sesin GP, Agani CAJO, Dos Santos TM, Brochier LSB, da Rosa BS, Tomazini BM, Besen BAMP, Pereira AJ, Veiga VC, Nascimento GM, Zavascki AP; OPTIMISE Study Group. Arns B, et al. Among authors: tomazini bm. Crit Care. 2024 Dec 18;28(1):412. doi: 10.1186/s13054-024-05178-6. Crit Care. 2024. PMID: 39695798 Free PMC article. Clinical Trial.
Daily Chlorhexidine Bath for Health Care Associated Infection Prevention (CLEAN-IT): protocol for a multicenter cluster randomized crossover open-label trial.
Tomazini BM, Veiga TS, Santos RHN, Campos VB, Tokunaga SM, Santos ES, Barbante LG, Maia RDC, Negrelli KL, Valeis N, Santucci EV, Laranjeira LN, Medrado FA Jr, Lisboa TC, Besen BAMP, Nassar Junior AP, Veiga VC, Pereira AJ, Cavalcanti AB. Tomazini BM, et al. Crit Care Sci. 2024 Sep 27;36:e20240053en. doi: 10.62675/2965-2774.20240053-en. eCollection 2024. Crit Care Sci. 2024. PMID: 39356897 Free PMC article.
VATICAN (Ventilator-Associated Tracheobronchitis Initiative to Conduct Antibiotic Evaluation): protocol for a multicenter randomized open-label trial of watchful waiting versus antimicrobial therapy for ventilator-associated tracheobronchitis.
IMPACTO-MR, VATICAN Trial Investigators and BRICNet; Tomazini BM, Besen BAMP, Dietrich C, Gandara APR, Silva DP, Pinheiro CCG, Luz MN, Mattos RR, Reis LFL, Roepke RML, Duarte CSLG, Nassar Júnior AP, Veiga VC, Arns B, Nascimento GM, Pereira AJ, Cavalcanti AB, Machado FR, Azevedo LCP. IMPACTO-MR, VATICAN Trial Investigators and BRICNet, et al. Among authors: tomazini bm. Crit Care Sci. 2024 Aug 26;36:e20240029en. doi: 10.62675/2965-2774.20240029-en. eCollection 2024. Crit Care Sci. 2024. PMID: 39194024 Free PMC article. Clinical Trial.
16S rRNA amplicon sequencing and antimicrobial resistance profile of intensive care units environment in 41 Brazilian hospitals.
de Bastiani DC, Silva CV, Christoff AP, Cruz GNF, Tavares LD, de Araújo LSR, Tomazini BM, Arns B, Piastrelli FT, Cavalcanti AB, de Oliveira LFV, Pereira AJ. de Bastiani DC, et al. Among authors: tomazini bm. Front Public Health. 2024 Jul 15;12:1378413. doi: 10.3389/fpubh.2024.1378413. eCollection 2024. Front Public Health. 2024. PMID: 39076419 Free PMC article.
Prospective, randomized, controlled trial assessing the effects of a driving pressure-limiting strategy for patients with acute respiratory distress syndrome due to community-acquired pneumonia (STAMINA trial): protocol and statistical analysis plan.
STAMINA Study Group Investigators; Maia IS, Medrado FA Jr, Tramujas L, Tomazini BM, Oliveira JS, Sady ERR, Barbante LG, Nicola ML, Gurgel RM, Damiani LP, Negrelli KL, Miranda TA, Santucci E, Valeis N, Laranjeira LN, Westphal GA, Fernandes RP, Zandonai CL, Pincelli MP, Figueiredo RC, Bustamante CLS, Norbin LF, Boschi E, Lessa R, Romano MP, Miura MC, Alencar Filho MS, Dantas VCS, Barreto PA, Hernandes ME, Grion CMC, Laranjeira AS, Mezzaroba AL, Bahl M, Starke AC, Biondi RS, Dal-Pizzol F, Caser EB, Thompson MM, Padial AA, Veiga VC, Leite RT, Araújo G, Guimarães M, Martins PA, Lacerda FH, Hoffmann Filho CR, Melro L, Pacheco E, Ospina-Táscon GA, Ferreira JC, Freires FJC, Machado FR, Cavalcanti AB, Zampieri FG. STAMINA Study Group Investigators, et al. Among authors: tomazini bm. Crit Care Sci. 2024 May 20;36:e20240210en. doi: 10.62675/2965-2774.20240210-en. eCollection 2024. Crit Care Sci. 2024. PMID: 38775567 Free PMC article.
Halofuginone for non-hospitalized adult patients with COVID-19 a multicenter, randomized placebo-controlled phase 2 trial. The HALOS trial.
Tomazini BM, Tramujas L, Medrado FA Junior, Gomes SPDC, Negrelli KL, Murinize GS, Santos RHN, Vianna BMP, Piotto BF, Veiga TS, Santos BRD, Peneluppi Horak AC, Lemos OMC, Lopes MA, Olicheski BB, Campones DL, Peixoto LAA, Basilio ADAC, Gebara OCE, Lopes ATA, Saconato H, Valeis N, Miranda TA, Laranjeira LN, Santucci EV, Carlin AF, Esko JD, Gordts PLSM, Tsimikas S, Cavalcanti AB. Tomazini BM, et al. PLoS One. 2024 Feb 23;19(2):e0299197. doi: 10.1371/journal.pone.0299197. eCollection 2024. PLoS One. 2024. PMID: 38394069 Free PMC article. Clinical Trial.
A Randomized, Open-Label, Non-inferiority Clinical Trial Assessing 7 Versus 14 Days of Antimicrobial Therapy for Severe Multidrug-Resistant Gram-Negative Bacterial Infections: The OPTIMISE Trial Protocol.
Arns B, Horvath JDC, Rech GS, Sesin GP, Agani CAJO, da Rosa BS, Dos Santos TM, Brochier LSB, Cavalcanti AB, Tomazini BM, Pereira AJ, Veiga VC, Nascimento GM, Kalil AC, Zavascki AP. Arns B, et al. Among authors: tomazini bm. Infect Dis Ther. 2024 Jan;13(1):237-250. doi: 10.1007/s40121-023-00897-9. Epub 2023 Dec 16. Infect Dis Ther. 2024. PMID: 38102448 Free PMC article.
29 results